Prescrire Int. 2010 Jun;19(107):135-7.
Once again, in 2009, most of the packaging that Prescrire analysed did not meet our quality criteria. Labelling information was too often ambiguous or clumsily expressed. The quality of dosing devices and the safety of multidose bottles were not guaranteed. Patient information leaflets were more legible on the whole, but once again rather uninformative. All of these shortcomings put patients at risk. European measures concerning drug labelling have finally been transposed into French law, and have led to some improvements: the international nonproprietary name (INN) is more frequently displayed on primary packaging. The use of Braille on boxes and access to Braille package leaflets are increasing. The improved legibility of the labelling of ampoules containing certain dangerous injectable drugs, as recommended by the French drug regulatory agency (Afssaps), has become more widespread. In practice, healthcare professionals need to take action on packaging issues: by choosing the best packaging, reporting potential sources of confusion and error and informing patients.
2009年，普雷斯crire分析的大部分包装再次不符合我们的质量标准。标签信息常常含糊不清或表述笨拙。给药装置的质量和多剂量瓶的安全性无法得到保证。患者信息单页总体上更清晰可读，但同样内容相当匮乏。所有这些缺陷都使患者面临风险。有关药品标签的欧洲措施最终已转化为法国法律，并带来了一些改进：国际非专利名称（INN）在药品外包装上的显示更为频繁。包装盒上使用盲文以及提供盲文包装说明书的情况有所增加。按照法国药品监管机构（法国药品安全局）的建议，含有某些危险注射用药物的安瓿瓶标签清晰度有所提高，这一情况更为普遍。实际上，医护人员需要就包装问题采取行动：选择最佳包装、报告潜在的混淆和错误来源并告知患者。
